# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian cancer

Cancer, Ovarian
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 61-70 of 605 results.
Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy
Status: Recruiting
Last Changed: Dec 05, 2019
First Received: Nov 14, 2019
Disease(s): Ovarian Cancer
Intervention(s): W_ova1 Vaccine
Locations: UMCG, Groningen, Netherlands
Comparative Effectiveness of HIPEC Following Interval Debulking Surgery in Patients With Advanced-stage Ovarian Cancer
Status: Recruiting
Last Changed: Jul 05, 2019
First Received: Feb 28, 2018
Disease(s): Ovarian Cancer
Intervention(s): HIPEC
Locations: Ajou University Hospital, Suwon, Gyeonggi, Korea, Republic of
Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer
Status: Recruiting
Last Changed: Oct 08, 2019
First Received: Jun 27, 2019
Disease(s): Ovarian Cancer
Intervention(s): Apatinib, Etoposide, Paclitaxel
Locations: Sun Yat-sen University, Guangzhou, Guangdong, China
Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients
Status: Recruiting
Last Changed: Dec 17, 2019
First Received: Sep 12, 2017
Disease(s): Ovarian Cancer
Intervention(s): Olaparib, Cediranib
Locations: Calvary Mater Hospital, Sydney, New South Wales, Australia
Campbelltown Hospital, Sydney, New South Wales, Australia
Prince of Wales Hospital, Sydney, New South Wales, Australia
Royal Hobart Hospital, Hobart, Tasmania, Australia
Border Medical Oncology, Albury, Australia
... and 29 other locations.
A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
Status: Recruiting
Last Changed: Oct 17, 2018
First Received: Oct 17, 2018
Disease(s): Ovarian Cancer
Intervention(s): ZL-2306 (Nirapairb), Placebo Comparator
Locations: Anhui Provincal Hospital, Hefei, Anhui, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
The first affiliated hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Guizhou Cancer hospital, Guiyang, Guizhou, China
... and 26 other locations.
Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer
Status: Not yet recruiting
Last Changed: May 29, 2018
First Received: May 29, 2018
Disease(s): Ovarian Cancer
Intervention(s): Pembrolizumab, Gemcitabine, Paclitaxel, Liposomal Doxorubicin
Locations: National Cancer Institute, Milan, Italy
A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Status: Recruiting
Last Changed: Jan 10, 2020
First Received: Jul 27, 2018
Disease(s): Ovarian Cancer
Intervention(s): Niraparib, Dostarlimab (TSR-042), Placebo
Locations: Alaska Women's Cancer Care, Anchorage, Alaska, United States
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
Hartford Hospital, Hartford, Connecticut, United States
University of Florida Health Cancer Center, Gainesville, Florida, United States
Cancer Specialists of North Florida, Jacksonville, Florida, United States
... and 134 other locations.
CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients
Status: Not yet recruiting
Last Changed: Feb 28, 2020
First Received: May 10, 2019
Disease(s): Ovarian Cancer, Resistant BRCA Wild-Type Ovarian Cancer
Intervention(s): Cohort 1: Dose Escalation, Cohort 2: Dose Escalation
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
Status: Recruiting
Last Changed: Dec 03, 2019
First Received: Nov 08, 2018
Disease(s): Ovarian Cancer Recurrent
Intervention(s): Rintatolimod, Pembrolizumab, Cisplatin
Locations: Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.
Status: Recruiting
Last Changed: Mar 16, 2020
First Received: Apr 11, 2017
Disease(s): Epithelial Ovarian Cancer
Intervention(s): Active Comparator: Olaparib tablets, Placebo
Locations: Research Site, Brussels, Belgium
Research Site, Leuven, Belgium
Research Site, Liège, Belgium
Research Site, Namur, Belgium
Research Site, London, Ontario, Canada
... and 101 other locations.